ABSTRACT
INTRODUCTION
Birth weight (BW) is an important factor that influences neonatal, infant and childhood morbidity and mortality. A fetus with an estimated weight (EFW) < 3 rd percentile or with a combination of EFW < 10 th percentile and abnormal umbilical artery blood flow is more likely to suffer from adverse perinatal outcome, such as cerebral palsy, compared with fetuses of appropriate weight for gestational age 1, 2 . Moreover, the Barker hypothesis suggests a link between low BW and cardiovascular disease in adulthood 3 .
Abnormally high uterine artery Doppler impedance is thought to reflect suboptimal uteroplacental perfusion and is strongly linked to compromised fetal growth. This has led to the hypothesis that placental function determines fetal growth. However, uterine artery flow is also influenced by maternal hemodynamics, such as plasma volume and cardiac output (CO). Prospective studies in early pregnancy have reported changes in maternal brachial blood pressure, heart rate and CO from as early as 5 weeks' gestation (1 week after embryonic implantation) in normal pregnancies 4 -7 . These changes plateau in the second or third trimester before returning to baseline values in the postpartum period 5, 8 .
Low maternal CO, insufficient plasma volume expansion and high peripheral vascular resistance (PVR) may predate fetal growth restriction (FGR) 9 -11 . In pregnancies complicated by pre-eclampsia (new-onset hypertension after 20 weeks' gestation and proteinuria in pregnancy), maternal CO in the first trimester is lower in women who subsequently had growth-restricted babies 12 . Thus, adequate maternal cardiovascular adaptation may be necessary for optimal uteroplacental perfusion and fetal growth 13 . The relationship between longitudinal maternal cardiovascular changes that occur from before to during pregnancy and fetal growth and BW in normal pregnancies has not been described previously. Understanding the magnitude and timing of these changes in normal pregnancy may clarify the role of cardiovascular maladaptation in conditions attributed to primary uteroplacental insufficiency, namely FGR and pre-eclampsia.
In this study, we investigated maternal cardiovascular adaptation, from before conception to mid-pregnancy, and its association with fetal growth trajectories and BW in normal pregnancy.
PATIENTS AND METHODS
This study was designed as a prospective feasibility study of recruitment and completion of follow-up for investigating maternal cardiovascular function from preconception to postpartum. The study was conducted at a single tertiary referral center. The study received Local Research Ethics Committee and Research and Development onsite approval. The methods have been described in detail in previous analyses of this cohort in relation to prepregnancy and early pregnancy changes 4 .
Study recruitment
Recruitment into the study was achieved through advertisements over a period of 11 months, from July 2010 to June 2011. Study posters were put up in the hospital in which the study was based, in GP surgeries in Cambridgeshire, on the hospital website, in local newspapers, preschool groups and National Childbirth Trust newsletters. The advertisements had the contact details of the lead research fellow, and women who were interested in participating could contact the research fellow by telephone or e-mail. In addition, contact details of women who had previous adverse obstetric history, such as pre-eclampsia, FGR or recurrent miscarriage, were obtained from databases of delivery and recurrent miscarriage clinics of the hospital in which the study was based.
The study inclusion criteria were: nulliparous women, parous women with previous normal pregnancy, previous pre-eclampsia and/or FGR, and women with previous unexplained recurrent miscarriage, aged between 18 and 50 years. Pre-eclampsia was defined by the criteria of the International Society for the Study of Hypertension in Pregnancy 14 . FGR was defined as a BW < 3 rd percentile 15 in the absence of congenital infection or aneuploidy.
Unexplained recurrent miscarriage was defined as more than three consecutive miscarriages < 12 weeks' gestation, for which investigations such as thrombophilia screening, cytogenetic examination of products of conception, pelvic ultrasound examination and parental peripheral blood karyotyping were negative and no specific problem was detected. The exclusion criteria were: smoking, history of thrombophilia (protein S or C deficiency, antithrombin II deficiency, positive lupus anticoagulant) and diabetes.
Study protocol
The study protocol is shown in Figure 1 . Women were recruited prior to conception and had baseline cardiovascular assessments as described below. They then performed digital home urine ovulation and pregnancy tests, as described in Figure 1 . The day of ovulation was estimated by adding 1 day to the day on which the luteinizing hormone surge was detected. The day of the first positive pregnancy test, using sensitive digital urine pregnancy test kits (SPD Development Company Ltd), was reported as the implantation day. Women who became pregnant were then followed up with serial ultrasound scans and repeat cardiovascular assessments in very early pregnancy, in the second and third trimesters and 3-4 months postpartum. Women who did not become pregnant at the end of the six cycles or who had either a miscarriage or ectopic pregnancy but wished to continue with the study were recruited back into the study. Their baseline cardiovascular assessments were not repeated.
Cardiovascular assessment
Cardiovascular measurements were performed after 10 min of rest with the woman in the supine left lateral position. Participants were requested to abstain from caffeinated drinks for 4 h prior to their visit. Brachial blood pressure (BP) and heart rate were measured in the non-dominant arm using an automated blood-pressure-measuring device (Omron-M7, White Medical, Rugby, UK) that has been validated for use in pregnancy 16 , using standard cuff sizes according to the arm circumference of the participant. Radial artery waveforms were obtained from the wrist with a high-fidelity micromanometer (SPC-301, Millar Instruments, Houston, TX, USA) and a corresponding central waveform was generated with a validated transfer function (SphygmoCor, AtCor Medical, Sydney, Australia) as described previously 17 -19 . Central systolic BP, mean arterial pressure and aortic augmentation index (AIx) were determined using the integrated software. Aortic stiffness was assessed by measuring the carotid-femoral (aortic) pulse-wave velocity with the same device 20 . The carotid-femoral distance was measured by ultrasound using calipers.
CO was assessed using a non-invasive, inert gas-rebreathing technique (Innocor, Innovision A/S, Odense S, Denmark), which has been validated previously against thermodilution 21 25 -28 . To assess whether pregnancy influenced measurement reproducibility, measurements of CO were performed in duplicate in the current study in a subset of 43 women (13 in prepregnancy, 20 in the second trimester and 10 in the third trimester) by asking participants to perform two rebreathing maneuvers, 5 min apart, in order to allow sufficient washout of the blood-soluble gas. The within-observer mean difference was 0.10 (95% CI, −0.9 to 1.1) L/min. The coefficient of variation between repeat readings was < 6%. There was no trend for the values to vary with time during pregnancy.
PVR was calculated from the formula: PVR (dynes × s/cm 5 ) = mean arterial pressure (mmHg) × 80/CO (L/min).
All measurements were performed in duplicate by a single, trained investigator (A.A.M.) and the mean values were used in subsequent analyses. The within-and between-observer measurement reproducibility values for the AIx were in agreement with previously published data 18 .
Ultrasound assessment
First-trimester growth was assessed by serial ultrasound measurement of embryonic crown-rump length (CRL) at 6-7, 8-9 and 10-14 weeks' gestation, according to the last menstrual period (LMP) in all women with a regular 28-day cycle, and in those for whom this was not the case, ultrasound examinations were scheduled from the date of the luteinizing hormone surge. The embryonic CRL was measured transvaginally at 6-7 and 8-9 weeks' gestation by placing the calipers at the outer sides of the crown and rump of the embryo in a longitudinal, midsagittal section. The fetal CRL at 10-14 weeks' gestation was imaged transabdominally in a midsagittal plane with the fetal spine longitudinally in view and the maximum CRL was measured to establish gestational age. Second-and third-trimester growth was assessed by deriving EFW using Hadlock's four-parameter model 29 at 20, 22-24 
Sample size
This was a feasibility study with no data available from any previous studies and thus a formal sample size calculation was not performed. We aimed to recruit 80 participants within the timescale of the study.
Statistical analysis
Statistical analyses were performed using the Statistical Package for Social Sciences (Version 18.0.0, 2009, SPSS, Chicago, IL, USA). Data are expressed as mean ± SD. The normality of distribution of the demographic data was examined by the Kolmogorov-Smirnov test. Univariate correlations between prepregnancy and pregnancy variables and fetal growth and BW were assessed using Spearman's correlation coefficient (ρ), and significance was assessed using a two-tailed t-test. P < 0.05 was considered significant.
RESULTS
In total, 184 women expressed an interest in participating in the study before conception. Of these, 143 women met the eligibility criteria and consented to participate ( Figure 2) ; 70 women were nulliparous and 35 Data are given as mean ± SD or n (%). GA, gestational age.
women were parous with previous normal pregnancy outcome. Twenty-six women with unexplained recurrent miscarriage and 12 women with a previous pregnancy complicated by pre-eclampsia and/or FGR were also recruited. A total of 101 women conceived within 18 months, of whom 71 had a viable pregnancy progressing beyond the first trimester. Five pregnancies subsequently developed complications (fetal chromosomal abnormalities, pre-eclampsia and/or FGR) and were excluded from final analyses, and two pregnancies were excluded due to incomplete datasets, leaving 64 normal pregnancies with complete longitudinal data available for analysis (Figure 2) . Demographics of the study population are shown in Table 1 . 
Relationship between fetal growth and birth weight
Results of the maternal cardiovascular and fetal growth assessments are summarized in Table 2 . The rate of second-to-third-trimester fetal growth was significantly associated with BW Z-score (ρ = 0.56, P < 0.001). The rate of first-trimester fetal growth was not associated with second-to-third-trimester fetal growth (ρ = 0.13,
Relationship between maternal cardiovascular changes from prepregnancy to second trimester and fetal growth and birth-weight Z-score
The changes in maternal CO (0.8 ± 1.2 L/min) and cardiac index (CI) (0.4 ± 0.6 L/min/m 2 ) from prepregnancy to the second trimester were positively correlated with BW Z-score (CO: ρ = 0.4, P = 0.004, Figure 3a ; CI: ρ = 0.3, P = 0.02) and second-to-third-trimester fetal growth (CO: ρ = 0.3, P = 0.02, Figure 3b ; CI: ρ = 0.3, P = 0.04). The reduction in PVR was significantly correlated with BW Z-score (ρ = 0.3, P = 0.02) and showed a trend in association with second-to-third-trimester fetal growth, but this was not significant (ρ = 0.3, P = 0.06) (Figure 4) . The reduction in AIx ( , −10 ± 9%) was significantly associated with second-to-third-trimester fetal growth (ρ = −0.3, P = 0.04). The decrease in brachial systolic blood pressure ( , −5 ± 8 mmHg) and central SBP ( , −9 ± 8 mmHg) from prepregnancy to the second trimester was not related to second-to-third-trimester fetal growth (ρ = 0.07, P = 0.6 and ρ = −0.06, P = 0.7, respectively) or BW Z-score (ρ = 0.06, P = 0.6 and ρ = −0.04, P = 0.8).
Overall, there was a significant rise in CO from a prepregnancy value of 5.56 ± 0.94 to 6.40 ± 1.09 L/min in the third trimester (P < 0.001). This was independent of body surface area as there was also a significant rise in CI from 3.15 ± 0.55 L/min/m 2 prepregnancy to 3.52 ± 0.53 L/min/m 2 in the third trimester (P < 0.001). Figure 3 Relationship in 64 pregnancies between change in maternal cardiac output (CO) from prepregnancy to second trimester and: (a) birth weight and (b) estimated fetal weight gain from second to third trimester.
However, there was a significant inverse association between the prepregnancy value of CO and the subsequent rise during pregnancy (r = −0.59, P < 0.001), which remained after adjusting for body surface area (CI: r = −0.59, P < 0.001).
Of the 64 women with complete longitudinal data, 11 had had a previous pregnancy with complications (recurrent miscarriage, pre-eclampsia or FGR). To exclude any possible bias from women with previous abnormal obstetric outcome, we performed a subanalysis including only women with a previous normal pregnancy outcome (n = 53). The pregnancy-induced AIx remained significantly associated with the second-to-third-trimester change in EFW (ρ = −0.3, P = 0.02) and BW Z-score (ρ = −0.3, P = 0.03). Changes in CO from prepregnancy to mid-pregnancy also remained significantly associated with the second-to-third-trimester change in EFW (ρ = 0.3, P = 0.05) but not with BW Z-score (ρ = 0.2, P = 0.07).
DISCUSSION
We found that maternal cardiovascular adaptation is related to fetal size and growth in normal pregnancy. We observed an increase in CO and CI from prepregnancy to the second trimester. Furthermore, the increase in CO is significantly positively associated with both BW and second-to-third-trimester fetal growth velocity, and a reduction in PVR is associated with a greater BW. Importantly, as reported previously 31 , the most substantial adaptations in CO and PVR occur early in the first trimester. The timing of these changes is crucial as they occur prior to the development of a functional placental unit at 12 weeks, suggesting that important adaptations of maternal cardiovascular hemodynamics precede this. The findings are likely to be valid as our sample size provided 99% power to detect an observed change in CO from prepregnancy to second trimester of 0.8 ± 1.2 L/min at P < 0.05.
We found no relationship between BP in the different trimesters of pregnancy and fetal growth or BW; however, data from the prospective Generation R study 32 suggest that higher BP is associated with a lower fetal weight from the third trimester. It should be noted that pregnancies with gestational hypertension and pre-eclampsia were included in their analyses and therefore lower BW may have been attributable to FGR and preterm delivery, which are strongly related to both conditions. It may be hypothesized that the relationships that we report are more pronounced in pathological pregnancies. It is important to note that this was a feasibility study in healthy pregnancies and was not powered for pathological outcomes, which occur in approximately 10% of pregnancies.
Studies of cardiac function in pathological pregnancies report that early-onset pre-eclampsia (< 34 weeks' gestation) is associated with reduced CO and high PVR; the inverse is observed in pregnancies with late-onset pre-eclampsia (> 34 weeks' gestation) 9, 12, 33 . In early-onset pre-eclampsia, there is a high likelihood of FGR, whereas in late-onset pre-eclampsia, BW is either normal or increased 10 . These observations, in relation to BW, are difficult to explain using the conventional placental hypothesis model of fetal growth, as the fetoplacental circulation is not established until 11-12 weeks' gestation, by which time major cardiovascular changes have occurred in the mother. The findings can, however, be explained if CO were a key determinant of fetal growth. If validated, particularly in pathological pregnancies, the findings would underpin a rationale for early identification of women at risk of poor pregnancy outcome. It might also raise the prospect of early therapy; oral volume loading and administration of vasodilators have been observed to improve fetal growth in early-onset pre-eclampsia and FGR 34 . The strength of this study is that it is the first to report preconception and pregnancy-induced cardiovascular changes in relation to BW and fetal growth velocity. In addition, parameters were measured in a longitudinal design, and therefore the observed changes are more likely to reflect true variation within the cohort. A weakness of the study is the relatively small sample size; although adequately powered to observe a change of 0.8 L/min in CO, it is likely to be insufficient to detect smaller changes. Further, we only included analyses of normal pregnancy outcome as the study was a feasibility study and not powered to observe changes in pathological pregnancy. There were five pathological pregnancy outcomes: two women delivered FGR babies before 34 weeks' gestation (one with pre-eclampsia) and one each with pre-eclampsia, FGR and pre-eclampsia/FGR after 34 weeks' gestation.
In conclusion, maternal cardiovascular changes in CO and PVR in the first half of pregnancy may play an important role in determining later fetal growth and BW. There is no association between cardiovascular changes and fetal size in the second trimester, suggesting that a larger fetus in the second trimester does not in turn lead to greater cardiovascular changes in the mother. The relationships are only evident when the cardiovascular changes are compared with a woman's baseline prepregnancy measures and perhaps explain why these associations have not been observed in studies conducted in established pregnancy.
